A novel, AI-generated morphologic biomarker to predict prostate cancer recurrence in patients with intermediate risk of progression. Model performance (root mean square error) in test of active ...

While the benefits of screening tests for cervical cancer, breast cancer, and colorectal cancer are widely accepted, screening for prostate cancer remains controversial to some. The main screening ...

Medicare covers one annual prostate-specific antigen (PSA) test for people with prostates if they meet the eligibility guidelines and the test is medically necessary. Medicare typically covers one ...

The understanding of prostate cancer has significantly evolved in the past 15 years. Therefore, many people — including primary care providers — may not be aware of the current guidelines for prostate ...